{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medium+Protein&page=2",
    "query": {
      "intervention": "Medium Protein",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medium+Protein&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T16:08:53.357Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00001077",
      "title": "A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections",
        "HIV Wasting Syndrome"
      ],
      "interventions": [
        {
          "name": "Multivitamin and mineral supplements",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Peptamen",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "NuBasics",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 536,
      "start_date": "1996-06",
      "completion_date": "1998-04",
      "has_results": false,
      "last_update_posted_date": "2013-10-01",
      "last_synced_at": "2026-09-25T16:08:53.357Z",
      "location_count": 17,
      "location_summary": "San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001077"
    },
    {
      "nct_id": "NCT04739800",
      "title": "Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Platinum-Refractory Fallopian Tube Carcinoma",
        "Platinum-Refractory Ovarian Carcinoma",
        "Platinum-Refractory Primary Peritoneal Carcinoma",
        "Recurrent Fallopian Tube Clear Cell Adenocarcinoma",
        "Recurrent Fallopian Tube Endometrioid Adenocarcinoma",
        "Recurrent Fallopian Tube High Grade Serous Adenocarcinoma",
        "Recurrent Fallopian Tube Mucinous Adenocarcinoma",
        "Recurrent Fallopian Tube Transitional Cell Carcinoma",
        "Recurrent Fallopian Tube Undifferentiated Carcinoma",
        "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma",
        "Recurrent Ovarian Clear Cell Adenocarcinoma",
        "Recurrent Ovarian Endometrioid Adenocarcinoma",
        "Recurrent Ovarian High Grade Serous Adenocarcinoma",
        "Recurrent Ovarian Low Grade Serous Adenocarcinoma",
        "Recurrent Ovarian Mucinous Adenocarcinoma",
        "Recurrent Ovarian Seromucinous Carcinoma",
        "Recurrent Ovarian Transitional Cell Carcinoma",
        "Recurrent Ovarian Undifferentiated Carcinoma",
        "Recurrent Platinum-Resistant Fallopian Tube Carcinoma",
        "Recurrent Platinum-Resistant Ovarian Carcinoma",
        "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma",
        "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma",
        "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma",
        "Recurrent Primary Peritoneal Transitional Cell Carcinoma",
        "Recurrent Primary Peritoneal Undifferentiated Carcinoma",
        "Refractory Fallopian Tube Clear Cell Adenocarcinoma",
        "Refractory Fallopian Tube Endometrioid Adenocarcinoma",
        "Refractory Fallopian Tube High Grade Serous Adenocarcinoma",
        "Refractory Fallopian Tube Mucinous Adenocarcinoma",
        "Refractory Fallopian Tube Transitional Cell Carcinoma",
        "Refractory Fallopian Tube Undifferentiated Carcinoma",
        "Refractory Low Grade Fallopian Tube Serous Adenocarcinoma",
        "Refractory Ovarian Clear Cell Adenocarcinoma",
        "Refractory Ovarian Endometrioid Adenocarcinoma",
        "Refractory Ovarian High Grade Serous Adenocarcinoma",
        "Refractory Ovarian Low Grade Serous Adenocarcinoma",
        "Refractory Ovarian Mucinous Adenocarcinoma",
        "Refractory Ovarian Seromucinous Carcinoma",
        "Refractory Ovarian Transitional Cell Carcinoma",
        "Refractory Ovarian Undifferentiated Carcinoma",
        "Refractory Primary Peritoneal Clear Cell Adenocarcinoma",
        "Refractory Primary Peritoneal Endometrioid Adenocarcinoma",
        "Refractory Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma",
        "Refractory Primary Peritoneal Transitional Cell Carcinoma",
        "Refractory Primary Peritoneal Undifferentiated Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cediranib Maleate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography with Contrast",
          "type": "PROCEDURE"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2021-06-10",
      "completion_date": "2027-06-25",
      "has_results": true,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-09-25T16:08:53.357Z",
      "location_count": 384,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04739800"
    },
    {
      "nct_id": "NCT00020267",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Adult Soft Tissue Sarcoma",
        "Colorectal Cancer",
        "Bone Cancer",
        "Ovarian Sarcoma",
        "Melanoma",
        "Colon Cancer",
        "Rectal Cancer",
        "Breast Cancer",
        "Eye Cancer",
        "Uterine Sarcoma"
      ],
      "interventions": [
        {
          "name": "interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "MAGE-12 peptide vaccine",
          "type": "DRUG"
        },
        {
          "name": "Montanide ISA-51",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-09-25T16:08:53.357Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020267"
    },
    {
      "nct_id": "NCT03302754",
      "title": "Precision Dosing of Alemtuzumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "6 Weeks to 30 Years"
      },
      "enrollment_count": 12,
      "start_date": "2017-10-05",
      "completion_date": "2019-03-10",
      "has_results": false,
      "last_update_posted_date": "2019-10-04",
      "last_synced_at": "2026-09-25T16:08:53.357Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03302754"
    },
    {
      "nct_id": "NCT00025181",
      "title": "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intraocular Melanoma",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tyrosinase peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 19,
      "start_date": "2001-10",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2014-05-22",
      "last_synced_at": "2026-09-25T16:08:53.357Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025181"
    },
    {
      "nct_id": "NCT00784719",
      "title": "A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "CP-690,550 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 327,
      "start_date": "2008-11",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-04-09",
      "last_synced_at": "2026-09-25T16:08:53.357Z",
      "location_count": 27,
      "location_summary": "Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00784719"
    },
    {
      "nct_id": "NCT04545008",
      "title": "Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Famotidine",
          "type": "DRUG"
        },
        {
          "name": "N-Acetyl cysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prisma Health-Upstate",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-10-20",
      "completion_date": "2021-06-02",
      "has_results": true,
      "last_update_posted_date": "2022-02-18",
      "last_synced_at": "2026-09-25T16:08:53.357Z",
      "location_count": 3,
      "location_summary": "Easley, South Carolina • Greenville, South Carolina • Greer, South Carolina",
      "locations": [
        {
          "city": "Easley",
          "state": "South Carolina"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Greer",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04545008"
    },
    {
      "nct_id": "NCT03058289",
      "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma",
        "Lymphoma",
        "Pancreatic Cancer",
        "Liver Cancer",
        "Colon Cancer",
        "Lung Cancer",
        "Bile Duct Cancer",
        "Chordoma of Sacrum",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "INT230-6",
          "type": "DRUG"
        },
        {
          "name": "anti-PD-1 antibody",
          "type": "BIOLOGICAL"
        },
        {
          "name": "anti-CTLA-4 antibody",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Intensity Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2017-02-09",
      "completion_date": "2023-02-22",
      "has_results": true,
      "last_update_posted_date": "2025-02-27",
      "last_synced_at": "2026-09-25T16:08:53.357Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03058289"
    },
    {
      "nct_id": "NCT03805789",
      "title": "The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acute-graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "AAT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 222,
      "start_date": "2019-03-27",
      "completion_date": "2026-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-25T16:08:53.357Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03805789"
    },
    {
      "nct_id": "NCT03430310",
      "title": "Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Low Glycemic Diet",
          "type": "OTHER"
        },
        {
          "name": "Control Diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 65,
      "start_date": "2018-10-09",
      "completion_date": "2023-07-31",
      "has_results": true,
      "last_update_posted_date": "2024-10-24",
      "last_synced_at": "2026-09-25T16:08:53.357Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03430310"
    }
  ]
}